ப்ரைம் திருத்துதல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Emerging from Stealth Mode, Gene Editing Startup Prime Medicine Raises $315M July 14, 2021 Source: CIPhotos/Getty Images Prime Medicine, whose “search and replace” approach to gene editing underpins the second genome editing technology to be commercialized by the lab of David R. Liu, Ph.D., and colleagues, said today it has completed $315 million in financing, ending nearly a year of operation in stealth mode. The financing consists of a $115 million Series A round and a $200 million series B round. Prime said proceeds from the financing will be used to continue building the company, rapidly advance towards clinical indications for its gene editing therapy candidates, and expand the capabilities of its platform.

Davidr liuKeith joungAndrew anzaloneKeith gottesdienerFeng zhangRegeneron pharmaceuticalsBroad instituteMerkin institute of transformative technologies in healthcareT rowe price associates incHarvard universityRedmile groupCold spring harbor laboratoryPrime medicineIntellia therapeuticsNew england journalRichard merkin professor